Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens continue to be the mainstay of treatment. However, immune checkpoint inhibitors are revolutionizing the treatment algorithm for this patient population with the 2016/2018 approvals of Merck & Co.’s Keytruda and Bristol-Myers Squibb / Ono Pharmaceutical’s Opdivo for previously treated recurrent or metastatic SCCHN and the 2019 approval of Merck & Co.’s Keytruda for the first-line recurrent or metastatic setting. Although SCCHN has historically proved to be a complex challenge for drug developers, many immune-oncology approaches and other drug classes are competing in late-phase development for SCCHN, both in the metastatic setting and in earlier stages of the disease. Several agents are being positioned for the untapped and lucrative locoregionally advanced SCCHN setting and are also poised to contribute to the robust market growth over the 2019-2029 forecast period.

Questions Answered

  • How large are the clinically and commercially relevant drug-treatable SCCHN populations, and how will drug-treatment rates change over time?
  • What is the current state of treatment for recurrent or metastatic SCCHN? What are interviewed experts’ views on these therapies?
  • Which pipeline products are poised to become options for the treatment of SCCHN, and what sales / uptake could they secure?
  • What are the key drivers and constraints in the SCCHN market, and how will the major markets evolve over the ten-year forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Squamous Cell Carcinoma Of The Head And Neck - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • December 2020
        • November 2020
      • Q3 2020
        • July 2020
      • Q2 2020
        • April 2020
        • March 2020
    • Key Findings
      • SCCHN - Key Findings
        • April 2020
        • March 2020
    • Market Outlook
      • Key Findings
        • Major-Market Share of SCCHN Drug Classes in 2019
        • Major-Market Share of SCCHN Drug Classes in 2029
        • Drug-Treatable Population Share and Major-Market Sales Share in SCCHN in 2019
        • Drug-Treatable Population Share and Major-Market Sales Share in SCCHN in 2029
        • Population Positioning of Therapies in SCCHN
        • SCCHN SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for SCCHN?
        • What Factors Are Constraining the Market for SCCHN?
        • Major-Market Sales for SCCHN by Region: 2019, 2024, and 2029
        • Major-Market Sales for SCCHN by Drug Class: 2019-2029
        • Major-Market Sales of Key Therapies for SCCHN: 2019-2029
      • Segment-Specific Trends
        • Patient-Share Dynamics of Key Treatments for Locoregionally Advanced Non-Nasopharyngeal SCCHN in the United States: 2019-2029
        • Major-Market Shares of Drug Classes for Locoregionally Advanced Non-Nasopharyngeal SCCHN: 2019-2029
        • Patient-Share Dynamics of Key Treatments for First-Line Non-Nasopharyngeal SCCHN in the United States: 2019-2029
        • Patient-Share Dynamics of Key Treatments for First-Line Nasopharyngeal SCCHN in the United States: 2019-2029
        • Major-Market Shares of Drug Classes for First-Line Non-Nasopharyngeal SCCHN: 2019-2029
        • Major-Market Shares of Drug Classes for First-Line Nasopharyngeal SCCHN: 2019-2029
        • Patient-Share Dynamics of Key Treatments for Second-Line Non-Nasopharyngeal SCCHN in the United States: 2019-2029
        • Patient-Share Dynamics of Key Treatments for Second-Line Nasopharyngeal SCCHN in the United States: 2019-2029
        • Patient Share Dynamics of Key Therapies in Third-Line Non-Nasopharyngeal SCCHN in the United States: 2019-2029
        • Patient Share Dynamics of Key Therapies in Third-Line Nasopharyngeal SCCHN in the United States: 2019-2029
        • Major-Market Shares of Drug Classes for Second- and Third-Line Non-Nasopharyngeal SCCHN: 2019-2029
        • Major-Market Shares of Drug Classes for Second- and Third-Line Nasopharyngeal SCCHN: 2019-2029
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
        • Disease Pathophysiology
          • Anatomy, Development, and Progression of SCCHN
          • Anatomy, Development, and Progression of SCCHN
          • Risk Factors Associated with SCCHN
          • Select Risk Factors Associated with SCCHN
        • Staging and Classification
          • Clinical Staging of SCCHN
          • Definition of TNM Staging Classification for Oral Cavity SCCHN
          • Definition of TNM Staging Classification of Hypopharyngeal SCCHN
          • Definition of TNM Staging Classification of Laryngeal SCCHN
          • TNM Staging System for Classification of Oral Cavity, Hypopharyngeal, and Laryngeal SCCHN
          • Definition of TNM Staging Classification for Oropharyngeal SCCHN
          • TNM Staging System for Classification of Oropharyngeal SCCHN
          • Definition of TNM Staging Classification of Nasopharyngeal SCCHN
          • TNM Staging System for Classification of Nasopharyngeal SCCHN
          • Composite TNM Staging and Treatment Overview of SCCHN
        • Key Pathways and Drug Targets
          • Key Pathways and Drug Targets in SCCHN
          • Immune Checkpoint Activation and Pathways
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Incidence of SCCHN
            • Number of Diagnosed Incident Cases of SCCHN in the Major Pharmaceutical Markets: 2020-2030
            • Number of Diagnosed Incident Cases of SCCHN by Site (Nasopharyngeal vs. Non-Nasopharyngeal): 2020-2030
            • Disease Definition
            • Methods
            • Sources Used for Stage Distribution of SCCHN
            • Number of Diagnosed Incident Cases of SCCHN in the Major Pharmaceutical Markets by Stage: 2020-2030
            • Disease definition
            • Methods
            • Sources Used for Recurrent Incidence of SCCHN
            • Metastatic Recurrent Incident Cases of SCCHN in Major Pharmaceutical Markets: 2020-2030
            • SCCHN Patient Flow
            • Sources Used for Drug-Treatable Populations of SCCHN
            • Drug-Treatable Cases of SCCHN (All Histologies): 2019-2029
            • Drug-Treatable Cases of Non-Nasopharyngeal SCCHN: 2019-2029
            • Drug-Treatable Cases of Nasopharyngeal SCCHN: 2019-2029
            • Sources Used for Drug-Treated SCCHN Populations
            • Drug-Treated Cases of SCCHN (All Histologies): 2019-2029
            • Drug-Treated Cases of Non-Nasopharyngeal SCCHN: 2019-2029
            • Drug-Treated Cases of Nasopharyngeal SCCHN: 2019-2029
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for SCCHN
            • Key Current Therapies
              • Overview
              • Current Treatments Used for SCCHN
              • Market Events Influencing the Use of Key Current Therapies in SCCHN
              • Mechanism of Action of Key Current Drugs Used for SCCHN
              • Key Results from Select Clinical Trials Investigating Erbitux for the Treatment of SCCHN
              • Ongoing Clinical Development of Erbitux
              • Expert Insight: Erbitux
              • Key Results from Select Clinical Trials Investigating Keytruda for the Treatment of SCCHN
              • Ongoing Clinical Development of Keytruda
              • Key Ongoing Clinical Trials of Keytruda in the Treatment of SCCHN
              • Expert Insight: Keytruda
              • Key Results from Select Clinical Trials Investigating Opdivo for SCCHN
              • Ongoing Clinical Development of Opdivo
              • Key Ongoing Clinical Trials of Opdivo in the Treatment of SCCHN
              • Expert Insight: Opdivo
              • Key Results from Select Clinical Trials Investigating Steboronine for the Treatment of SCCHN
              • Ongoing Clinical Development of Steboronine
              • Key Results from Select Clinical Trials Investigating Akalux for the Treatment of SCCHN
              • Ongoing Clinical Development of Akalux
              • Key Ongoing Clinical Trials of Akalux in the Treatment of SCCHN
              • Expert Insight: Akalux
            • Medical Practice
              • Early-Stage Localized (Stage I/II) SCCHN
              • Locoregionally Advanced (Stage III/IVA/IVB) SCCHN
              • First-Line Recurrent or Metastatic SCCHN
              • Second- and Third-Line Recurrent or Metastatic SCCHN
              • Treatment Guidelines
              • Patient Characteristics Influencing Drug Selection in SCCHN
              • Treatment Decision Tree for Early-Stage Localized (Stage I/II) SCCHN
              • Treatment Decision Tree for Locoregionally Advanced (Stage III/IVA/IVB) SCCHN
              • Treatment Decision Tree for Recurrent or Metastatic SCCHN
          • Unmet Need Overview
            • Current and Future Attainment of Unmet Needs in SCCHN
            • Top Unmet Needs in SCCHN: Current and Future Attainment
          • Emerging Therapies
            • Key Findings
              • Key Emerging Therapies
                • Key Therapies in Development for SCCHN
                • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of SCCHN
                • Key Results from Select Clinical Trials Investigating Yervoy for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Yervoy
                • Key Ongoing Clinical Trials of Yervoy in the Treatment of SCCHN
                • Expert Insight: Yervoy
                • Expectations for Market Authorization and Sales Opportunity of Yervoy in SCCHN
                • Key Results from Select Clinical Trials Investigating Imfinzi for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Imfinzi
                • Key Ongoing Clinical Trials of Imfinzi in the Treatment of SCCHN
                • Expert Insight: Imfinzi
                • Expectations for Market Authorization and Sales Opportunity of Imfinzi in SCCHN
                • Analysis of Clinical Development Program for Tremelimumab
                • Expert Insight: Tremelimumab
                • Expectations for Market Authorization and Sales Opportunity of Tremelimumab in SCCHN
                • Key Results from Select Clinical Trials Investigating Bavencio for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Bavencio
                • Key Ongoing Clinical Trials of Bavencio in the Treatment of SCCHN
                • Expert Insight: Bavencio
                • Expectations for Market Authorization and Sales Opportunity of Bavencio in SCCHN
                • Key Results from Select Clinical Trials Investigating Tecentriq for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Tecentriq
                • Key Ongoing Clinical Trials of Tecentriq in the Treatment of SCCHN
                • Expert Insights: Tecentriq
                • Expectations for Market Authorization and Sales Opportunity of Tecentriq in SCCHN
                • Key Results from Select Clinical Trials Investigating Monalizumab for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Monalizumab
                • Key Ongoing Clinical Trials of Monalizumab in the Treatment of SCCHN
                • Expert Insight: Monalizumab
                • Expectations for Market Authorization and Sales Opportunity of Monalizumab in SCCHN
                • Key Results from Select Clinical Trials Investigating Toripalimab for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Toripalimab
                • Expert Insight: Toripalimab
                • Expectations for Market Authorization and Sales Opportunity of Toripalimab in SCCHN
                • Key Results from Select Clinical Trials Investigating Rovaleucel for the Treatment of SCCHN
                • Analysis of the Clinical Development Program for Rovaleucel
                • Key Ongoing Clinical Trials of Rovaleucel in the Treatment of SCCHN
                • Expert Insight: Rovaleucel
                • Expectations for Market Authorization and Sales Opportunity of Rovaleucel in SCCHN
                • Key Results from Select Clinical Trials Investigating Multikine for the Treatment of SCCHN
                • Analysis of the Clinical Development Program for Multikine
                • Key Ongoing Clinical Trials of Multikine in the Treatment of SCCHN
                • Expert Insight: Multikine
                • Expectations for Market Authorization and Sales Opportunity of Multikine in SCCHN
                • Key Results from Select Clinical Trials Investigating Lenvima for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Lenvima
                • Key Ongoing Clinical Trials of Lenvima in the Treatment of SCCHN
                • Expert Insight: Lenvima
                • Expectations for Market Authorization and Sales Opportunity of Lenvima in SCCHN
                • Key Results from Select Clinical Trials Investigating Xevinapant for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Xevinapant
                • Key Ongoing Clinical Trials of Xevinapant in the Treatment of SCCHN
                • Expert Insight: Xevinapant
                • Expectations for Market Authorization and Sales Opportunity of Xevinapant in SCCHN
                • Key Results from Select Clinical Trials Investigating Feladilimab (GSK3359609) for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Feladilimab (GSK3359609)
                • Key Ongoing Clinical Trials of Feladilimab (GSK3359609) in the Treatment of SCCHN
                • Expert Insight: Feladilimab (GSK3359609)
                • Expectations for Market Authorization and Sales Opportunity of Feladilimab (GSK3359609) in SCCHN
                • Key Results from Select Clinical Trials Investigating Buparlisib for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Buparlisib
                • Key Ongoing Clinical Trials of Buparlisib in the Treatment of SCCHN
                • Expert Insight: Buparlisib
                • Expectations for Market Authorization and Sales Opportunity of Buparlisib in SCCHN
                • Key Results from Select Clinical Trials Investigating Tipifarnib for the Treatment of SCCHN
                • Analysis of Clinical Development Program for Tipifarnib
                • Key Ongoing Clinical Trials of Tipifarnib in the Treatment of SCCHN
                • Expectation for Market Authorization and Sales Opportunity of Tipifarnib in SCCHN
              • Early-Phase Pipeline Analysis
              • Access and Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in SCCHN: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in SCCHN: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in SCCHN: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • SCCHN Bibliography

            Author(s): Carolina do Pazo, M.Sc.; Neela Rambaruth

            Carolina do Pazo, M.Sc., is a senior analyst on the Oncology team at Clarivate. She has authored content on breast cancer, SCCHN, ovarian cancer, and prostate cancer. Previously, she was a research scientist at the Institut Pasteur de Montevideo, where she analyzed the aging process of yeast cells, and she was part of a project between Indiana University and the Universidad ORT that analyzed the production of nanohybrids for drug delivery system applications. As a Chevening Scholar, Ms. Do Pazo completed an M.Sc. in biotechnology, bioprocessing, and business management with distinction at the University of Warwick. She also earned her first-class M.Eng. in biotechnology from the Universidad ORT.

            Neela Rambaruth, M.Sc., Ph.D., is an analyst on the Oncology team at DRG, part of Clarivate. She has authored content on non-small-cell lung cancer and hepatocellular carcinoma. Prior to joining DRG, she was a postdoctoral scientist at University College London, where she investigated the interaction of novel drugs with a therapeutic receptor involved in cardiovascular disease. She also held a postdoctoral position at Imperial College London, where she studied host-pathogen interaction in tuberculosis. She received her Ph.D. in breast oncology from the University of Westminster. Her doctorate focused on the identification of novel biomarkers associated with metastatic breast cancer. She has also published several peer-reviewed articles on oncology and therapeutic drug discovery.


            Related Reports

            Squamous Cell Carcinoma of the Head and Neck | Disease Landscape and Forecast | G7 | 2020

            Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens continue to be the mai...

            View Details